Alison Liddy | BiotechTV

top of page

Align Summit 2026: Relevium Medical is developing what it believes is the first TRPV1 agonist that mitigates the burning tolerability issue seen with others in the past

Co-Founder & CEO Alison Liddy describes Relevium's program, which is designed to be an extended release prodrug. The initial clinical indication will be osteoarthritis of the knee. Coverage brought to you by

Company News

5 hours ago

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

Learn more

bottom of page

Align Summit 2026: Relevium Medical is developing what it believes is the first TRPV1 agonist that mitigates the burning tolerability issue seen with others in the past

Follow BiotechTV

Sponsors

Sponsor Spotlight